v3.25.3

License and Collaboration Agreements - Aarvik (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		14 Months Ended
	Aug. 31, 2024	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Jun. 30, 2023
Agreement
Research and development		$ 32,167	$ 20,088	$ 121,176	$ 58,841
Collaborative Agreement \| Aarvik
Agreement
Maximum payment on statements of work							$ 3,100
Initiation fee							$ 300
Amount of payment to exercise option to license and/or acquire certain intellectual property	$ 1,000
Maximum amount payable per product upon achievement of certain clinical and regulatory milestone events	18,000
Maximum amount payable per product upon achievement of commercial milestones	$ 80,000
Amount paid for initiation fee and research fees						$ 5,200
Research and development		$ 200	$ 1,900	$ 500	$ 3,100

Payment amount made for initiation fees and research fees under the agreement.

+ References

No definition available.

+ Details

Name:	avbp_ArrangementInitiationAndResearchFeesPayment
Namespace Prefix:	avbp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of initiation fee payable under the agreement.

+ References

No definition available.

+ Details

Name:	avbp_ArrangementInitiationFee
Namespace Prefix:	avbp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Maximum amount payable per product upon achievement of certain clinical and regulatory milestone events.

+ References

No definition available.

+ Details

Name:	avbp_ArrangementMaximumPaymentPerProductClinicalAndRegulatoryMilestones
Namespace Prefix:	avbp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Maximum amount payable per product upon achievement of commercial milestones.

+ References

No definition available.

+ Details

Name:	avbp_ArrangementMaximumPaymentPerProductCommercialMilestones
Namespace Prefix:	avbp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Maximum amount required to be paid on the statements of work under the agreement.

+ References

No definition available.

+ Details

Name:	avbp_ArrangementMaximumPaymentStatementOfWork
Namespace Prefix:	avbp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payment amount made upon exercise of option to license and/or acquire certain intellectual property.

+ References

No definition available.

+ Details

Name:	avbp_ArrangementOptionToLicenseAndAcquireIntellectualPropertyPayment
Namespace Prefix:	avbp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avbp_AarvikPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ArriVent BioPharma, Inc. 10-Q